“Macrodosing” Sublingual Buprenorphine and Extended-release Buprenorphine in a Hospital Setting: 2 Case Reports

OBJECTIVES To describe 2 case reports in which high-dose administration of sublingual buprenorphine/naloxone quickly stabilized fentanyl users who presented to the hospital. To discuss how early administration of extended-release buprenorphine, before the patient is discharged, may improve retention rates for outpatient buprenorphine treatment. METHODS Two case reports of fentanyl users presented to the emergency department at the general hospital in Timmins, Canada are described. They were rapidly stabilized on high-dose sublingual buprenorphine/naloxone and then transitioned within 24 to 36 hours to buprenorphine extended-release subcutaneous injection. RESULTS In both cases, their withdrawal symptoms quickly resolved, without sedation or precipitated withdrawal. Both patients followed up with the outpatient clinic for another injection of extended-release buprenorphine. CONCLUSIONS High-dose sublingual buprenorphine/naloxone followed by early administration of extended-release buprenorphine quickly and safely relieved withdrawal symptoms in 2 fentanyl users who presented to the hospital emergency department. This novel approach shows promise in improving treatment retention rates for patients using fentanyl. Further research is required to evaluate the safety and effectiveness of this approach.

[1]  J. Hobelmann,et al.  Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl , 2021, Journal of addiction medicine.

[2]  B. Linas,et al.  Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study , 2021, The Lancet. Public health.

[3]  E. Nunes,et al.  Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. , 2021, Addiction.

[4]  Nasir H. Naqvi,et al.  Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl. , 2021, The American journal on addictions.

[5]  J. Dziura,et al.  High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder , 2021, JAMA network open.

[6]  K. Brady,et al.  Retention in Treatment after Emergency Department-Initiated Buprenorphine. , 2021, The Journal of emergency medicine.

[7]  P. Haber,et al.  Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine , 2021, JAMA network open.

[8]  J. Moe,et al.  Microdosing and standard‐dosing take‐home buprenorphine from the emergency department: A feasibility study , 2020, Journal of the American College of Emergency Physicians Open.

[9]  A. Slaunwhite,et al.  Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study , 2020, BMJ.

[10]  Nasir H. Naqvi,et al.  Case Series: Rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users. , 2020, The American journal on addictions.

[11]  M. Greenwald,et al.  Rapid induction onto sublingual buprenorphine after opioid overdose and successful linkage to treatment for opioid use disorder. , 2019, American Journal of Emergency Medicine.

[12]  A. Russolillo,et al.  Characteristics of adherence to methadone maintenance treatment over a 15-year period among homeless adults experiencing mental illness , 2017, Addictive behaviors reports.

[13]  G. D’Onofrio,et al.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. , 2015, JAMA.